Arfolitixorin - a drug candidate
for treatment of colorectal cancer

Read more >>

See how arfolitixorin
works in cancer cells

See the animation >>

The global Phase III study AGENT

The AGENT study with arfolitixorin

is ongoing at more than 90 hospitals

in The US, Canada, Europe, Australia and Japan

Read More >>

Previous

Next

Startpage 2

Upcoming Events

  • August 21, 2020 - August 21, 2020
    Interim Report Q2 2020
  • September 03, 2020 - September 03, 2020
    Pareto Securities´ Health Care Conference, Stockholm
  • October 05, 2020 - October 06, 2020
    HealthTech Innovation Days, Paris
  • November 13, 2020 - November 13, 2020
    Interim Report Q3 2020